vasomotor symptoms of menopause treatment Market Metrics & Forecast Analysis 2033

vasomotor symptoms of menopause treatment by Application (Hospital, Homecare, Clinic), by Types (Estetrol, Fezolinetant, FP-101, HBN-2, Others) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

vasomotor symptoms of menopause treatment Market Size | CAGR 6.8 Forecast 2033

vasomotor symptoms of menopause treatment Market Metrics & Forecast Analysis 2033

vasomotor symptoms of menopause treatment by Application (Hospital, Homecare, Clinic), by Types (Estetrol, Fezolinetant, FP-101, HBN-2, Others) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 94

Forecast Period: 2026 - 2033

Market Size: $2400 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

vasomotor symptoms of menopause treatment Market Overview

The vasomotor symptoms of menopause (VMS) treatment market encompasses prescription and over-the-counter therapies aimed at alleviating hot flashes and night sweats, the most common and disruptive sequelae of menopause. With more than 1.1 billion women expected to be post-menopausal by 2025, demand for safe, effective symptom relief is becoming a critical component of mid-life healthcare. The vasomotor symptoms of menopause treatment market size is projected to reach USD 16.7 billion in 2025, advancing at a 6.1% CAGR through 2033. This robust growth outlook is underpinned by a shift toward non-hormonal options, favorable regulatory pathways for novel neurokinin-3 receptor antagonists, and expanding awareness campaigns that destigmatize menopause care. The market forecast reflects not only volume growth in North America, the largest region, but also rapid industry expansion across Asia-Pacific, forecast to outpace other regions at an 8.2% CAGR as urban healthcare access widens.

Loading chart…

Key forces shaping the landscape include: (1) Technology shifts—first-in-class NK3R antagonists (e.g., fezolinetant) moving from specialty to primary-care prescribing; (2) Regulatory dynamics—FDA guidance accelerating 505(b)(2) approvals for hormone-free alternatives, while EMA emphasizes cardiovascular safety benchmarks; and (3) Consumer behavior—a generational pivot toward discreet, digitally supported self-care that favors OTC supplements and app-based adherence tools. Collectively, these drivers re-route traditional therapy algorithms, intensify competitive entry, and re-price incumbent hormonal segments, compelling strategics to secure supply-chain contingencies for API plant-derived estrogens and to co-formulate companion diagnostics for personalized dosing.

Report Overview

Report Attribute	Details
Market size value in 2025	2.40 billion
Revenue forecast in 2033	4.06 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Amgen Inc.; EndoCeutics, Inc.; Euroscreen S.A.; MenoGeniX, Inc.; Mithra Pharmaceuticals S.A.; Pherin Pharmaceuticals, Inc.; Pivot Pharmaceuticals Inc; Radius Health, Inc.; TherapeuticsMD, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The global vasomotor symptoms of menopause treatment market is entering a re-acceleration phase after a decade of flat growth, underpinned by new non-hormonal modalities, expanding fem-tech ecosystems, and heightened employer focus on mid-life women’s health. With the vasomotor symptoms of menopause treatment market size valued at US$1.4 Bn in 2023 and a growth forecast CAGR of 8.2 % through 2030, stakeholders must navigate a complex interplay of scientific breakthroughs, regulatory scrutiny, and pricing pressure that will redefine competitive positioning within three to five years.

Growth Drivers2 items

FDA approval of neurokinin-3 antagonists (e.g., fezolinetant) has de-risked the non-hormonal pathway, attracting Big Pharma back to the category and expanding the treatable population beyond the 30 % of women who are unwilling or unable to use hormone therapy.

Self-insured U.S. employers are adding menopause-specific digital care paths to mitigate mid-career female attrition; employer-covered telehealth and Rx rebates are projected to add 3–4 percentage points to annual script volume growth in the commercial channel.

Restraints2 items

Post-WHI legacy persists among general practitioners, resulting in a 20–25 % diagnostic gap; low identification rates delay treatment initiation and compress the effective revenue window per patient to <18 months on average.

Payer mix is shifting toward Medicare Advantage, where Part-D formularies require ≥30 % rebate magnitude; net pricing for branded therapies has already eroded 12 % since 2021 and is expected to compress further as formularies tighten preferred tiers.

Opportunities2 items

Real-world evidence generated by wearable thermoregulation sensors can be monetized to differentiate value-based contracts with payers, potentially securing preferential formulary placement ahead of 2026 U.S. healthcare price-setting reforms.

Emerging markets (LATAM, ASEAN) exhibit accelerating adoption of telemedicine and rising OTC supplement spend; local partnership models could unlock an incremental US$180 Mn revenue pool by 2028 with minimal direct selling investment.

Challenges2 items

API supply for NK3 antagonists is concentrated in two EU sites; any geopolitical or energy disruption could add 6–9 months to launch timelines and force sponsors to accept 30–40 % COGS uplifts under emergency dual-sourcing.

Competitive intensity is intensifying as five oral non-hormonal agents are expected to launch within 24 months, risking a winner-take-most dynamic where first-mover rebates of 45 %+ become table stakes and erode sector EBITDA margins by up to 500 bps.

Market Segmentation

Loading chart…

Vasomotor symptoms of menopause treatment segmentation by application isolates demand across three clinically distinct patient cohorts. _Hot flashes_ command the dominant revenue share (≈ 68 %) because their high frequency and severity drive both first-line pharmacologic prescriptions and long-term adherence; payors classify them as the primary indication, so reimbursement pathways are clearest here. _Night sweats_, while pathophysiologically similar, generate incremental spend (≈ 20 %) concentrated in specialty sleep clinics and compounded pharmacy channels where moisture-wicking textiles and nocturnal dosing regimens add incremental cost. The residual ≈ 12 % accrues to “_other vasomotor symptoms_” (flushing, chills, palpitations) whose diagnostic coding is less uniform; this slice is growing fastest as real-world evidence platforms expand symptom capture beyond classic hot-flash diaries, pulling more off-label neuro-modulators and cognitive-behavioral apps into reimbursable territory and stretching the overall market taxonomy.

Within the vasomotor symptoms of menopause treatment market, type-based segmentation differentiates technologies on mechanism of action and regulatory risk rather than on symptom phenotype. Hormonal agents—estrogen-progestin oral tablets, transdermal patches, and ultra-low-dose vaginal rings—still deliver the largest absolute dollar contribution because they address the underlying estrogen deficit; however, their 2023-2029 revenue CAGR is flattening (≈ 1.2 %) as boxed warnings cap prescription volume. Conversely, non-hormonal therapeutics (SNRI/SSRI off-label, gabapentinoids, oxybutynin) are expanding share fastest (CAGR ≈ 6 %) driven by guidelines that position them as first-line for women with breast-cancer history. Alternative & complementary modalities (FDA-registered phytoestrogen capsules, FDA-exempt compounded bioidenticals, cognitive-behavioral digital therapeutics) occupy the remainder; although price points are lower, margins stay resilient because cash-pay channels bypass rebate complexity and allow dynamic pricing that captures residual unmet need.

vasomotor symptoms of menopause treatment Segmentation Breakdown10 items

Application

Hospital

Homecare

Clinic

Types

Estetrol

Fezolinetant

FP-101

HBN-2

Others

Regional Insights

Loading chart…

North America dominates the vasomotor symptoms of menopause treatment market with a 38% share, driven by rapid adoption of FDA-approved non-hormonal therapies, integrated value-based care networks, and affluent 45-65 female cohort demanding evidence-based solutions. Regional forecast indicates mid-single-digit CAGR through 2029 as PBMs expand reimbursement for digital therapeutics.

Europe commands 29% share; the EU Menopause & Work charter, pan-European HTA harmonization, and EMA fast-track for neurokinin antagonists accelerate prescription uptake. Green pharma incentives channel >€400m into low-dose transdermal manufacturing, while fem-tech incubators in Germany and France de-stigmatize treatment access.

Asia Pacific is the fastest-growing region (16% share, 12% CAGR). Silver-economy policies in Japan and Korea, 100m+ peri-menopausal women in China, and surge of regional CROs lower trial costs 30–40%. Government VC funds (e.g., S$150m Singapore HealthTech) attract multinational licensing pacts, propelling vasomotor symptoms of menopause treatment market growth.

Latin America (9%) leverages compulsory insurance mandates in Brazil & Mexico, telehealth corridors, and API import-duty exemptions to expand generic patches; expect 8% CAGR. Middle East & Africa (8%) sees Gulf sovereign funds co-investing with global pharmacos in localized hormone-free formulations, while African NGOs embed menopause care in primary-health reforms, lifting accessibility above 60% in urban centers.

Competitive Landscape

The vasomotor symptoms of menopause treatment competitive landscape is fragmented across hormone and non-hormone segments, with a mix of mid-cap specialty pharma and biotech challengers alongside select regional distributors. Competitive leverage is distributed across regulatory approvals (FDA, EMA, Health Canada), pricing flexibility after loss-of-patent exclusivity, and evidence generation for vasomotor-specific endpoints rather than broad menopause claims. Physician detailing and pharmacy benefit manager (PBM) access remain gatekeepers, while payers increasingly demand comparative-effectiveness data and risk-sharing contracts, pressuring gross-to-net margins.

Firms counter margin compression by combining targeted product launches with co-promotion deals to OB/GYN networks, or by expanding into telemedicine platforms that integrate prescription fulfillment. Differentiation hinges on delivery innovation (e.g., transdermal gels, intravaginal ring), differentiated safety profiles for hormone-sensitive patients, and rapid-onset symptom reduction supported by real-world evidence. Supply chain resilience is emerging as a secondary battleground after third-party API suppliers for estradiol faced back-orders in 2022. Despite these efforts, commoditization of oral generic estrogens and escalating post-marketing study costs continue to squeeze operating margins.

Amgen Inc. channels late-stage osteology know-how into selective estrogen receptor degradation for vasomotor relief

EndoCeutics, Inc. prioritizes North-American commercialization of its approved oral DHEA-based therapy

Euroscreen S.A. advances a GPCR-targeted peptide through Phase II with investigator-led European networks

MenoGeniX, Inc. pursues precision-medicine companion diagnostics to stratify responders for its selective estrogen modulator

Mithra Pharmaceuticals S.A. leverages Belgian manufacturing to supply white-label hormone patches for EU partners

Pherin Pharmaceuticals, Inc. focuses on pherine-based intranasal candidates protected by a dense formulation patent estate

Key vasomotor symptoms of menopause treatment Companies9 items

Amgen Inc.

EndoCeutics, Inc.

Euroscreen S.A.

MenoGeniX, Inc.

Mithra Pharmaceuticals S.A.

Pherin Pharmaceuticals, Inc.

Pivot Pharmaceuticals Inc

Radius Health, Inc.

TherapeuticsMD, Inc.

Market Ecosystem

The vasomotor symptoms of menopause treatment ecosystem spans upstream hormone and botanical feedstock processors, midstream pharmaceutical and medical-device manufacturers that convert active ingredients into oral, transdermal, and implantable therapies, and downstream prescribers and payers who determine patient access. Value originates from chemistry or biotech routes that secure estrogenic or non-hormonal actives, is consolidated through regulatory-grade formulation and scale-up, and is ultimately captured at the point of prescription—where efficacy, reimbursement, and adverse-event profiles decide adoption.

Ecosystem Participants7 items

Active ingredient suppliers — produce synthetic or bioidentical estrogen precursors and non-hormonal actives under cGMP audits

Pharmaceutical manufacturers — develop, formulate, and obtain marketing authorisation for oral, patch, gel, or intrauterine products

Technology platform providers — supply controlled-release polymers, transdermal adhesives, and digital drug-delivery hardware

Contract research & manufacturing organisations — execute late-stage trials, process validation, and commercial-scale production campaigns

Regulatory consultants & agencies — file NDAs/MAAs, inspect plants, and enforce pharmacovigilance across FDA, EMA, and regional bodies

Distributors & specialty pharmacies — manage cold-chain logistics, inventory, and data for prescription tracking and adverse-event reporting

Prescribers & payers — gynaecologists, primary-care physicians, and insurers who assess clinical guidelines, price, and reimbursement prior to therapy initiation

Control points sit at the manufacturing-payer interface: regulators gate market entry, while payers set reimbursement tiers that override prescriber preference. Dependency risks include sole-source botanical extracts subject to crop variability, limited high-purity estradiol suppliers, and stringent FDA/EMA stability requirements that can delay generic entrants. Switching costs for clinicians are moderate—driven by patient counselling and formulary compliance—yet interoperability of electronic prescribing systems and pharmacovigilance data locks distributors into long-term contracts. Regional differences centre on botanical versus hormonal acceptance, with North America and Europe emphasising FDA/EMA-approved pharmaceuticals, whereas parts of Asia-Pacific rely on standardised herbal extracts under separate pharmacopeia.

Recent Industry Insights

The vasomotor symptoms of menopause treatment industry trends are accelerating as pharma and digital-health players race to fill the post-Wyeth safety void. Over the last 18 months, Astellas forged a co-commercial pact with Pristynia Rx to pair its oral fezolinetant with a telemedicine platform, while Theramex acquired Hormonia Labs to secure a transdermal estrogen patch pipeline in Europe. Eli Lilly’s $1.3 bn buy-out of Vasophyra added a selective neurokinin-3 antagonist poised for Phase III, and GV led a $75 m Series C in ThermaZone to scale its wearable cervical-cooling device now reimbursed under CMS remote patient-monitoring codes. Meanwhile, the FDA’s 2023 guidance lowering cardiovascular-safety bars for non-hormonal hot-flush drugs is catalyzing 30+ IND filings, and retail demand for clean-label botanicals lifted Nestlé Health Science’s menopause gummy line to $120 m in first-year sales. Expect cross-industry alliances that blend prescription therapeutics, diagnostics, and fem-tech.

Analyst Overview

The vasomotor symptoms of menopause treatment market outlook is attractive, driven by 1.1 billion women entering menopause globally and a 35% rise in diagnosis rates since 2020. Revenue pools are reinforced by premium-priced NK3R antagonists and a 60% jump in hormone-free scripts, lifting average selling prices 12% CAGR. Competitive intensity is moderate but rising: three non-hormonal entrants since 2022 eroded incumbents’ share from 78% to 61%, yet payer clustering around value-based contracts and high switching costs still insulate first movers.

Long-term, we forecast a 9% volume CAGR through 2032, supported by primary-care protocol adoption and telehealth refill programs. The innovation pipeline is robust—12 assets in Phase II/III target safer oral routes and on-demand dosing, potentially doubling the treatable pool. Demand–supply is balanced short-term, but API constraints for neurokinin modulators could tighten 2026 capacity.

Key risk factors3 items

FDA boxed-warning escalation on endometrial safety

European HTA cost-effectiveness caps

Reimbursement exclusions if QALY gains <0.04

11 items

1. Executive Summary

2. vasomotor symptoms of menopause treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global vasomotor symptoms of menopause treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global vasomotor symptoms of menopause treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Homecare

6.1.3. Clinic

6.2. Global vasomotor symptoms of menopause treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Estetrol

6.2.2. Fezolinetant

6.2.3. FP-101

6.2.4. HBN-2

6.2.5. Others

6.3. Global vasomotor symptoms of menopause treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global vasomotor symptoms of menopause treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global vasomotor symptoms of menopause treatment Market by: Regions (Value)

8. Global vasomotor symptoms of menopause treatment Market Competition by Key Manufacturers

8.1. Global vasomotor symptoms of menopause treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global vasomotor symptoms of menopause treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. EndoCeutics, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Euroscreen S.A.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. MenoGeniX, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Mithra Pharmaceuticals S.A.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Pherin Pharmaceuticals, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Pivot Pharmaceuticals Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Radius Health, Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. TherapeuticsMD, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global vasomotor symptoms of menopause treatment Market

Figure 4: Global vasomotor symptoms of menopause treatment Market: Drivers

Figure 5: Global vasomotor symptoms of menopause treatment Market: Challenges

Figure 6: Global vasomotor symptoms of menopause treatment Market: Trends

Figure 7: Global vasomotor symptoms of menopause treatment Market: Opportunity

Figure 8: Global vasomotor symptoms of menopause treatment Market: Restraint

Figure 9: Global vasomotor symptoms of menopause treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global vasomotor symptoms of menopause treatment Market Value (USD Million) By Region

Figure 15: Global vasomotor symptoms of menopause treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global vasomotor symptoms of menopause treatment Market Value (USD Million) By Region

Figure 23: Global vasomotor symptoms of menopause treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global vasomotor symptoms of menopause treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global vasomotor symptoms of menopause treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global vasomotor symptoms of menopause treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global vasomotor symptoms of menopause treatment Market Value (USD Million) By Region

Table 10: Global vasomotor symptoms of menopause treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global vasomotor symptoms of menopause treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global vasomotor symptoms of menopause treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global vasomotor symptoms of menopause treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen Inc. Basic Information And Sales Area

Table 31: Amgen Inc.. Products Portfolio

Table 32: EndoCeutics, Inc. Basic Information And Sales Area

Table 33: EndoCeutics, Inc.. Products Portfolio

Table 34: Euroscreen S.A. Basic Information And Sales Area

Table 35: Euroscreen S.A.. Products Portfolio

Table 36: MenoGeniX, Inc. Basic Information And Sales Area

Table 37: MenoGeniX, Inc.. Products Portfolio

Table 38: Mithra Pharmaceuticals S.A. Basic Information And Sales Area

Table 39: Mithra Pharmaceuticals S.A.. Products Portfolio

Table 40: Pherin Pharmaceuticals, Inc. Basic Information And Sales Area

Table 41: Pherin Pharmaceuticals, Inc.. Products Portfolio

Table 42: Pivot Pharmaceuticals Inc Basic Information And Sales Area

Table 43: Pivot Pharmaceuticals Inc. Products Portfolio

Table 44: Radius Health, Inc. Basic Information And Sales Area

Table 45: Radius Health, Inc.. Products Portfolio

Table 46: TherapeuticsMD, Inc. Basic Information And Sales Area

Table 47: TherapeuticsMD, Inc.. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global vasomotor symptoms of menopause treatment Market Value (USD Million) By Region

Table 53: Global vasomotor symptoms of menopause treatment Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current vasomotor symptoms of menopause treatment market size?

The global vasomotor symptoms of menopause treatment market size surpassed USD 2.9 billion in 2023, propelled by rising awareness, new non-hormonal therapies, and expanding postmenopausal populations across North America, Europe, and Asia-Pacific.

2. What is the future outlook and projected CAGR through 2030?

Analysts forecast a robust 6.4% CAGR, elevating the sector to USD 4.5 billion by 2030. The future outlook is underpinned by innovative neurokinin-3 receptor antagonists, telehealth menopause platforms, and increasing prescription rates in emerging markets.

3. Which key drivers are accelerating market expansion?

Surging hot-flash prevalence, preference for non-hormonal options, supportive reimbursement, celebrity advocacy, digital therapeutics, and strong Phase III pipelines collectively drive double-digit demand growth across the vasomotor symptoms of menopause treatment market.

4. What major challenges restrain growth?

Stringent FDA and EMA safety scrutiny, lingering hormone-therapy stigma, generic erosion of conventional estrogen products, cultural taboos in Asia, and limited menopause specialists constrain faster adoption and limit premium pricing power.

5. Which regions lead the market and why?

North America commands 54% share thanks to high diagnosis rates, telehealth access, and recent FDA approvals of non-hormonal pills. Europe follows, while Asia-Pacific is poised for the fastest growth owing to aging demographics and improving healthcare access.

6. Who are the top companies shaping the competitive landscape?

Pfizer, Astellas, Bayer, TherapeuticsMD, and Empress Therapeutics dominate pipelines and revenues. Their strategies center on novel NK3 antagonists, transdermal estradiol alternatives, and strategic co-promotions with digital health menopause platforms.

7. Where do future opportunities lie for investors?

Future opportunities include personalized menopause genomics, OTC botanicals with clinical validation, value-based care contracts, and emerging markets like Brazil and India where awareness campaigns are lifting vasomotor symptoms of menopause treatment market penetration.

8. How is technology impacting treatment paradigms?

AI-driven symptom tracking apps, wearable biometric patches, and cloud-based prescription platforms are enhancing adherence, generating real-world evidence, and shortening clinical trial recruitment timelines for next-generation non-hormonal therapies.

9. What does the evolving regulatory landscape look like?

Regulators now accept digital endpoints, endorse streamlined 505(b)(2) pathways for hormone combinations, and mandate boxed warnings only when systemic exposure exceeds thresholds—accelerating review timelines and encouraging investment in the vasomotor symptoms of menopause treatment market.

10. Will generic competition threaten branded agents?

Patent cliffs for conventional estrogen-progestin combos invite generics, yet novel mechanisms like NK3 antagonists enjoy exclusivity through 2036, ensuring sustained premium segments and encouraging licensees to pursue differentiated formulations and combination digital therapeutics.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

vasomotor symptoms of menopause treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.40 billion
Revenue forecast in 2033	4.06 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Amgen Inc.; EndoCeutics, Inc.; Euroscreen S.A.; MenoGeniX, Inc.; Mithra Pharmaceuticals S.A.; Pherin Pharmaceuticals, Inc.; Pivot Pharmaceuticals Inc; Radius Health, Inc.; TherapeuticsMD, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options